Mieloma múltiple

+ -Text Size

Otros recursos y referencias TEMAS

Referencias: guía detallada del mieloma múltiple

Alexander DD, Mink PJ, Adami HO, et al. Multiple myeloma: a review of the epidemiologic literature. Int J Cancer. 2007;120 Suppl 12:40-61.

American Cancer Society. Cancer Facts and Figures 2015. Atlanta, GA: American Cancer Society; 2015.

Dores GM, Coté TR, Travis LB. New Malignancies Following Hodgkin Lymphoma, Non-Hodgkin Lymphoma, and Myeloma. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. National Cancer Institute. NIH Publ. No. 05-5302. Bethesda, MD, 2006. Accessed on 4/18/2014 at http://seer.cancer.gov/archive/publications/mpmono/MPMonograph_complete.pdf.

Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-3420.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER website, April 2013.

Kyle RA, Rajkumar SV. Multiple myeloma. New Eng J Med. 2004;351:1860-1873

Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, Gapstur S, Patel AV, Andrews K, Gansler T; American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012 Jan-Feb;62(1):30-67.

Leleu X, Attal M, Arnulf B, et al. Pomalidomide plus low dose dexamethasone is active and well tolerated in bortezomib and lenalidomide refractory multiple myeloma: IFM 2009-02. Blood. 2013;121(11):1968-1975. Epub 2013 Jan 14.

Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438-447.

National Cancer Institute. Physician Data Query (PDQ). Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment. 11/8/2013. Accessed at www.cancer.gov/cancertopics/pdq/treatment/myeloma/healthprofessional on March 5, 2014.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Multiple myeloma. V.2.2014. Accessed at www.nccn.org on March 5, 2014.

Munshi NC, Anderson KC. Plasma cell neoplasms. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 9th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2011:1997-2032.

Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.

Raje N, Hideshima T, Anderson KC. Plasma cell tumors. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E. Cancer Medicine 6. Hamilton, Ontario: BC Decker; 2003:2219-2244.

Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov;15(12):e538-e548. Epub 2014 Oct 26.

Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders. In: Niederhuber JE, Armitage JO, Doroshow JH,. Kastan MB, Tepper JE. Abeloff’s Clinical Oncology. 5th edition. Philadelphia, PA. Elsevier: 2014:1991-2017.

Richardson PG, Schlossman RL, Alsina M, et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood. 2013;122(14):2331-2337. Epub 2013 Aug 15.

San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066. Epub 2013 Sep 3.

Sirohi B, Powles R. Multiple Myeloma. Lancet 2004;363:875-887.

Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma. Br J Haematol. 2005;132:410-452.


Fecha de última actualización: 07/31/2014
Fecha de último cambio o revisión: 03/09/2015